ArticleOncology letters2024

Safety evaluation of lenvatinib treatment after atezolizumab plus bevacizumab therapy for patients with unresectable liver cancer: A comparison of lenvatinib as 1st‑ or 2nd‑line treatment.

Michio Kimura et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.